scholarly journals Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction

2014 ◽  
Vol 80 (6) ◽  
pp. 918-924 ◽  
Author(s):  
Janka Hindricks ◽  
Thomas Ebert ◽  
Anette Bachmann ◽  
Susan Kralisch ◽  
Ulrike Lössner ◽  
...  
Keyword(s):  
Growth Factor ◽  
Renal Dysfunction ◽  
Fibroblast Growth Factor ◽  
Serum Levels ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Acute Renal Dysfunction

scholarly journals HIGHER SERUM LEVELS OF FIBROBLAST GROWTH FACTOR 21 IN GERIATRIC PATIENTS WITH CACHEXIA

2018 ◽  
Vol 2 (suppl_1) ◽  
pp. 300-300
Author(s):  
K Franz ◽  
M Ost ◽  
C Herpich ◽  
L Otten ◽  
V Coleman ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Geriatric Patients ◽  
Serum Levels ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth

Higher serum levels of fibroblast growth factor 21 in old patients with cachexia

Nutrition ◽  
2019 ◽  
Vol 63-64 ◽  
pp. 81-86 ◽  
Author(s):  
Kristina Franz ◽  
Mario Ost ◽  
Lindsey Otten ◽  
Catrin Herpich ◽  
Verena Coleman ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Serum Levels ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Old Patients

Serum levels of the adipokine fibroblast growth factor-21 are increased in preeclampsia

Cytokine ◽  
2013 ◽  
Vol 62 (2) ◽  
pp. 322-326 ◽  
Author(s):  
Holger Stepan ◽  
Karoline Kley ◽  
Janka Hindricks ◽  
Susan Kralisch ◽  
Alexander Jank ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Serum Levels ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth

scholarly journals SAT-046 Insulin-Like Growth Factor and Fibroblast Growth Factor 21 in Men with Klinefelter Syndrome

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Simon Chang ◽  
Rikke Hjortebjerg ◽  
Anders Bojesen ◽  
Mette Bjerre ◽  
Claus Hojbjerg Gravholt
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Klinefelter Syndrome ◽  
Protein A ◽  
Serum Levels ◽  
Fibroblast Growth Factor 21 ◽  
Control Group ◽  
Insulin Like Growth Factor ◽  
Fibroblast Growth ◽  
Igf System

Abstract Background: Men with 47, XXY Klinefelter syndrome (KS) commonly present with obesity, metabolic disorders, and insulin insensitivity. The insulin-like growth factor (IGF) system has pleiotropic effects including regulation of glucose metabolism. Fibroblast growth factor 21 (FGF21) is associated with weight loss and favourable metabolic changes, but patients with obesity or type 2 diabetes might be resistant to this effect despite presenting with increased levels. Aim: To describe levels of components in the IGF system and FGF21 among men with KS, either treated or not treated with testosterone supplementation therapy (TT), in comparison with control males. Methods: A total of 66 men with KS were included, 33 without current TT and 33 with current TT. A control group of 70 healthy age-matched males were included. Serum levels of insulin-like growth factor 1 (IGF-1), insulin-like growth factor-binding protein 3 (IGFBP3), pregnancy-associated plasma protein A (PAPP-A), FGF21, and fibroblast activation protein (FAP) were compared between the three groups applying the Kruskal-Wallis test. Results: Levels of (IGF-1 µg/L) were not different between the groups (median (25-75 %), untreated KS 162 (140-201.5), treated KS 165 (128.5-215), controls 176.5 (150.8-214.5), p=0.5). Similarly, FGF21 levels (ng/L) were comparable between the groups (median (25-75 %), untreated KS 84.7 (53.3-217.6), treated KS 97.2 (56.4-224.8), controls 100.3 (66.0-191.0), p=0.9). Levels of IGFBP3, PAPP-A and FAP were also found to be comparable between the groups (p≥0.2). Conclusion: This was the first study investigating FGF21 in men with KS. Our results indicate that regulation of the IGF-1 system and levels of FGF21 are not altered in men with KS compared with age-matched controls, and that TT in men with KS does not affect these systems.

Effects of fibroblast growth factor 21 on cell damage in vitro and atherosclerosis in vivo

2014 ◽  
Vol 92 (11) ◽  
pp. 927-935 ◽  
Author(s):  
Wenhe Zhu ◽  
Changwen Wang ◽  
Lei Liu ◽  
Yan Li ◽  
Xiaokun Li ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Cell Damage ◽  
Density Lipoprotein ◽  
Serum Levels ◽  
Lipoprotein Cholesterol ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth

Fibroblast growth factor 21 (FGF-21), which is a modulator of glucose and lipid homeostasis, acts as a novel therapeutic reagent for many metabolic perturbations. However, its potential as a treatment for cardiovascular disease, especially atherosclerosis (AS) has not been fully explored. Here, we report that recombinant FGF-21 improves resistance to cell damage from oxidative stress in vitro, and from atherosclerosis in vivo. Human umbilical vein endothelial cells (HUVECs) were induced with H2O2, followed by treatment with high purity recombinant FGF-21. The results indicated that FGF-21 significantly enhanced cell viability and decreased the degree of DNA fragmentation in HUVECs, as caused by H2O2 stress induction. Further studies revealed that FGF-21 inhibited H2O2-induced cell apoptosis by preventing the activation of mitogen-activated protein kinase (MAPK) signaling pathways. In an established rat model, FGF-21 dramatically improved the condition of atherosclerotic rats by decreasing serum levels of total triglyceride (TG), low density lipoprotein cholesterol (LDL-C), and total cholesterol (TC), and by increasing the serum levels of high density lipoprotein cholesterol (HDL-C). FGF-21 also has antioxidant effects in the atherosclerotic rat, such that increased levels of superoxide dismutase, reduced glutathione, and reduced malondialdehyde were observed. These data provide novel insight into the potential use of FGF-21 in the prevention and treatment of human cardiovascular diseases.

scholarly journals Higher serum levels of fibroblast growth factor 21 in geriatric patients with cachexia

2018 ◽  
Vol 37 ◽  
pp. S28-S29
Author(s):  
K. Franz ◽  
M. Ost ◽  
C. Herpich ◽  
L. Otten ◽  
A.-S. Endres ◽  
...  
Keyword(s):  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Geriatric Patients ◽  
Serum Levels ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth

scholarly journals Association between Circulating Fibroblast Growth Factor 21 and Aggressiveness in Thyroid Cancer

Cancers ◽  
2019 ◽  
Vol 11 (8) ◽  
pp. 1154 ◽  
Author(s):  
Yea Eun Kang ◽  
Jung Tae Kim ◽  
Mi Ae Lim ◽  
Chan Oh ◽  
Lihua Liu ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Growth Factor ◽  
Fibroblast Growth Factor ◽  
Kinase Inhibitor ◽  
Serum Levels ◽  
Human Thyroid ◽  
Fibroblast Growth Factor 21 ◽  
Fibroblast Growth ◽  
Tumor Aggressiveness ◽  
Mesenchymal Transition

Fibroblast growth factor 21 (FGF21) plays important roles in regulating glucose, lipid, and energy metabolism; however, its effects in tumors remain poorly understood. To understand the role of FGF21 in regulating tumor aggressiveness in thyroid cancer, serum levels of FGF21 were measured in healthy subjects and patients with papillary thyroid cancer (PTC), and expression levels of FGF21, FGF receptors (FGFRs), and β-klotho (KLB) were investigated in human thyroid tissues. The cell viability, migrating cells, and invading cells were measured in PTC cells after treatment with recombinant FGF21. Higher serum levels of FGF21 were found in patients with thyroid cancer than in control participants, and were significantly associated with body mass index (BMI), fasting glucose levels, triglyceride levels, tumor stage, lymphovascular invasion, and recurrence. Serum FGF21 levels were positively correlated with the BMI in patients with PTC, and significantly associated with recurrence. Recombinant FGF21 led to tumor aggressiveness via activation of the FGFR signaling axis and epithelial-to-mesenchymal transition (EMT) signaling in PTC cells, and AZD4547, an FGFR tyrosine kinase inhibitor, attenuated the effects of FGF21. Hence, FGF21 may be a new biomarker for predicting tumor progression, and targeting FGFR may be a novel therapy for the treatment of obese patients with PTC.

Sign in / Sign up

Export Citation Format

Share Document